From: Insights into estrogen impact in oral health & microbiome in COVID-19
Variables | Premenopausal n = 20 | Postmenopausal n = 18 | Men n = 22 | P value |
---|---|---|---|---|
Age | 33.55 ± 7.14 | 56.56 ± 10.25 | 37.55 ± 10.96 | 0.0001* |
Weight (kg) | 73.45 ± 15.95 | 67.94 ± 13.83 | 88.95 ± 18.38 | 0.0004* |
Height (m) | 1.62 ± 0.06 | 1.55 ± 0.05 | 1.75 ± 0.06 | 0.0001* |
Serum estrogen (pg/mL) | 88 ± 84 | 46 ± 56 | 25 ± 8 | 0.0001* |
Saliva estrogen (pg/mL) | 1.19 ± 0.49 | 0.98 ± 0.42 | 0.92 ± 0.33 | 0.1630 |
Comorbidities | ||||
Yes (%) | 7 (35) | 14 (77.8) | 10 (45.5) | 0.0238 + |
No (%) | 13 (65) | 4 (22.2) | 12 (54.5) | |
Hypertension | - | 4 (28.6) | 2 (20) | |
Diabetes | 1 (14.3) | 3 (21.4) | 1 (10) | |
Obesity | 6 (85.7) | 7 (50) | 7 (70) | |
Body Mass Index (%) | ||||
Normal Weight | 7 (35) | 4 (22.2) | 3(13.6) | 0.4459 |
Overweight | 7 (35) | 7 (38.8) | 12 (54.5) | |
Obesity | 6 (30) | 7 (38.8) | 7 (31.9) | |
SARS-CoV-2 | ||||
Viral Load (copies/mL) | 8.24 × 106 ± 16 × 106 | 10.4 × 106 ± 14 × 106 | 4.9 × 106 ± 10 × 107 | 0.7225 |
High (> 100,000 copies/mL) | 15(75%) | 11(61.1%) | 15(68.2%) | |
Moderate (10,000 -100,000 copies/mL) | 2(10%) | 5(27.8%) | 4(18.2%) | |
No detecteda | 3(15%) | 2(11.1) | 3(13.6%) | |
Oral Health | ||||
DMF-T | 4.6 ± 4.03 | 7.6 ± 3.27 | 4.45 ± 3 | 0.01⤒ |
CAVITY CARIES (D component) | 1.4 ± 2 | 0.88 ± 1.77 | 2.09 ± 1.84 | 0.0483 |
OHI-S | 1.12 ± 0.88 | 1.52 ± 1.21 | 1.55 ± 0.79 | 0.2983 |